A new market study, titled “Global Immunotherapy Drugs Market Size Study, by Type of Drugs (Monoclonal Antibodies, Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha & Beta, Interleukins, Others) by Therapy Area (Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases, Others) by End-Use (Hospitals, Clinics, Others) by Regional Forecasts 2017-2025”, has been featured on WiseGuyReports.
Global Immunotherapy Drugs Market valued approximately USD 108.5 billion in 2016 is anticipated to grow with a healthy growth rate of more than 14.0% over the forecast period 2017-2025. Faster drug approval processes, rising prevalence of life style-oriented diseases, and rising adoption of targeted therapies are the primary growth drivers for global immunotherapy drugs market. However, the market growth is restricted by the high cost of immunotherapy treatment.
Global Immunotherapy market is segmented by type of drugs, therapy area and end-use. Based on therapy area the market is segmented into cancer, autoimmune & inflammatory diseases, infectious diseases, and others. Among these, currently the market is dominated by cancer segment which is anticipated to account for 33% revenue share in 2016. The cancer segment will continue to dominate over the forecast period and is also anticipated to register the highest growth over the forecast period. Increasing prevalence of cancer and rising adoption of immunotherapy for cancer treatment is driving the market growth.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type of Drugs:
Monoclonal Antibodies
Adult Vaccines
o Preventive Vaccines
o Therapeutic Vaccines
Checkpoint Inhibitors
Interferons Alpha & Beta
Interleukins
Other Drugs
By Therapy Area:
Cancer
Autoimmune & Inflammatory Diseases
Infectious Diseases
Other Therapy Area
By End-Use:
Hospitals
Clinics
Other End Users
Request Sample Report at https://www.wiseguyreports.com/sample-request/3136526-global-immunotherapy-drugs-market-size-study-by-type
By Regions:
North America
o U.S.
o Canada
Europe
o UK
o Germany
Asia Pacific
o China
o India
o Japan
Latin America
o Brazil
o Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2015
Base year – 2016
Forecast period – 2017 to 2025
Some of the key manufacturers involved in the market F.Hoffmann, Merck & Co., Inc., Novartis International AG, Johnson & Johnson (A Parent Company of Jannssen Biotech, Inc.), Glaxosmithkline PLC, Amgen Inc., Abbvie, Amstrazeneca, Bristol-Mysers Squibb, ELI Lilly & Company Frequent cross industry partnerships are leading to market consolidation.
Table of Content
Chapter 1. Global Immunotherapy Drugs Market Definition and Scope
Chapter 2. Research Methodology
Chapter 3. Executive Summary
Chapter 4. Global Immunotherapy Drugs Market Dynamics
Chapter 5. Global Immunotherapy Drugs Market, by Type of Drug
Chapter 6. Global Immunotherapy Drugs Market, by Therapy Area
Chapter 7. Global Immunotherapy Drugs Market, by End-Use
Chapter 8. Global Immunotherapy Drugs Market, by Regional Analysis
Chapter 9. Competitive Intelligence
About Us:
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Contact Us:
NORAH TRENT
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
